GC
AEGR

Guggenheim Capital’s Aegerion Pharmaceuticals AEGR Stock Holding History

Guggenheim Capital’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-10,124
Closed -$30K – 3063
2016
Q3 		$30K Buy
+10,124
New +$17.5K ﹤0.01% 2791
2015
Q3 		– Sell
-189,734
Closed -$3.6M – 3076
2015
Q2 		$3.6M Sell
189,734
-154,977
-45% -$3.35M 0.01% 1336
2015
Q1 		$9.02M Buy
344,711
+222,633
+182% +$5.67M 0.02% 900
2014
Q4 		$2.56M Buy
122,078
+30,797
+34% +$776K 0.01% 1542
2014
Q3 		$3.05M Buy
91,281
+2,144
+2% +$66.5K 0.01% 1475
2014
Q2 		$2.86M Sell
89,137
-3,776
-4% -$141K 0.01% 1523
2014
Q1 		$4.29M Buy
92,913
+22,826
+33% +$1.34M 0.01% 1212
2013
Q4 		$4.97M Buy
70,087
+9,127
+15% +$698K 0.02% 1095
2013
Q3 		$5.22M Buy
60,960
+7,298
+14% +$619K 0.02% 1077
2013
Q2 		$3.4M Buy
+53,662
New +$2.85M 0.01% 1231

Guggenheim Capital's AEGR Position: Q4 2016 in Review

Guggenheim Capital sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 10,124 shares — an estimated $30K sold.

Guggenheim Capital first reported a position in AEGR in Q2 2013 and held it in 10 quarters. The position peaked at $9.02M in Q1 2015. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

  • Guggenheim Capital reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Guggenheim Capital sold 10,124 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $30K.
  • Guggenheim Capital first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 10 quarters.
  • Guggenheim Capital's Aegerion Pharmaceuticals position peaked at $9.02M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on Guggenheim Capital's 13F filing for Q4 2016, filed 14 Feb 2017.